Faculty profile

Robert Day

ResearcherSurgeryUniversité de Sherbrooke

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a Université de Sherbrooke directory, so their courses may be missing. Find their university profile.

Robert Day

Researcher

Surgery

Université de Sherbrooke

Sherbrooke, Quebec, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
4 publications in the last five years, latest in 2023.
Senior (last) author on 2 recent papers, a sign of leading a research group.
Principal investigator on 2 research grants (2 CIHR), most recently in 2019.
Supervisor on 5 trainee awards (5 CIHR), most recently in 2018.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Collaborators

Grants

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

C23 Cancer Animal Models Drug Delivery Enzyme Inhibitor Imaging Medicinal Chemistry Pace4 Prodrugs

Latest papers

Enhancing the Drug-Like Profile of a Potent Peptide PACE4 Inhibitor by the Formation of a Host-Guest Inclusion Complex with β-Cyclodextrin.
Molecular pharmaceutics · 2023
Cleavage of the V-ATPase associated prorenin receptor is mediated by PACE4 and is essential for growth of prostate cancer cells.
PloS one · 2023
Efficacy of PACE4 pharmacotherapy in JHU-LNCaP-SM preclinical model of androgen independent prostate cancer.
Scientific reports · 2022 · senior author

All 50 publications

Latest funding

Set-up of a mass spectrometry-based stool test for colorectal cancer screening
CIHR · 2020 · Co-investigator
$719,101
High affinity inhibitors of PACE4 with therapeutic implications for prostate cancer
CIHR · 2019 · Nominated PI
$696,150
Découverte de biomarqueurs en relation avec la PACE4 à l'aide d'une approche multiomique par spectrométrie de masse pour le cancer de la prostate
CIHR · 2018 · Supervisor
$105,000

All 9 grants and awards

50 publications.

Enhancing the Drug-Like Profile of a Potent Peptide PACE4 Inhibitor by the Formation of a Host-Guest Inclusion Complex with β-Cyclodextrin.

Navals P, Kwiatkowska A, Mekdad N, Couture F, Desjardins R, Day R, Dory YL

Molecular pharmaceutics2023

DOI: 10.1021/acs.molpharmaceut.3c00261 PMID: 37555521

Cleavage of the V-ATPase associated prorenin receptor is mediated by PACE4 and is essential for growth of prostate cancer cells.

Mohammad AH, Couture F, Gamache I, Chen O, El-Assaad W, Abdel-Malak N, Kwiatkowska A, Muller W, Day R, Teodoro JG

PloS one2023

DOI: 10.1371/journal.pone.0288622 PMID: 37463144

Efficacy of PACE4 pharmacotherapy in JHU-LNCaP-SM preclinical model of androgen independent prostate cancer.

Mekdad N, Tran TMH, Desjardins R, Kwiatkowska A, Couture F, Day R

Scientific reports2022Senior author

DOI: 10.1038/s41598-022-21593-7 PMID: 36261691

PACE4-altCT isoform of proprotein convertase PACE4 as tissue and plasmatic biomarker for prostate cancer.

Couture F, Wang L, Dufour F, Chabot-Maheux K, Ekindi Ndongo N, Sabbagh R, Day R

Scientific reports2022Senior author

DOI: 10.1038/s41598-022-09778-6 PMID: 35410344

Design and Structure-Activity Relationship of a Potent Furin Inhibitor Derived from Influenza Hemagglutinin.

Lewandowska-Goch MA, Kwiatkowska A, Łepek T, Ly K, Navals P, Gagnon H, Dory YL, Prahl A, Day R

ACS medicinal chemistry letters2021Senior author

DOI: 10.1021/acsmedchemlett.0c00386 PMID: 33738063

Mast Cell Degranulation Increases Mouse Mast Cell Protease 4-Dependent Vasopressor Responses to Big Endothelin-1 But Not Angiotensin I.

Vincent L, Lapointe C, Lo M, Gagnon H, Pejler G, Takai S, Day R, D'Orléans-Juste P

The Journal of pharmacology and experimental therapeutics2021

DOI: 10.1124/jpet.120.000325 PMID: 33154104

Upregulation of PACE4 in prostate cancer is not dependent on E2F transcription factors.

Bakrania A, Aubé M, Desjardins R, Sabbagh R, Day R

Canadian journal of physiology and pharmacology2020Senior author

DOI: 10.1139/cjpp-2019-0668 PMID: 32119574

The motif EXEXXXL in the cytosolic tail of the secretory human proprotein convertase PC7 regulates its trafficking and cleavage activity.

Durand L, Duval S, Evagelidis A, Guillemot J, Dianati V, Sikorska E, Schu P, Day R, Seidah NG

The Journal of biological chemistry2020

DOI: 10.1074/jbc.ra119.011775 PMID: 31915245

Functional analysis of natural PCSK9 mutants in modern and archaic humans.

Mikaeeli S, Susan-Resiga D, Girard E, Ben Djoudi Ouadda A, Day R, Prost S, Seidah NG

The FEBS journal2020

DOI: 10.1111/febs.15036 PMID: 31386798

Ser-Phosphorylation of PCSK9 (Proprotein Convertase Subtilisin-Kexin 9) by Fam20C (Family With Sequence Similarity 20, Member C) Kinase Enhances Its Ability to Degrade the LDLR (Low-Density Lipoprotein Receptor).

Ben Djoudi Ouadda A, Gauthier MS, Susan-Resiga D, Girard E, Essalmani R, Black M, Marcinkiewicz J, Forget D, Hamelin J, Evagelidis A, Ly K, Day R, Galarneau L, Corbin F, Coulombe B, Çaku A, Tagliabracci VS, Seidah NG

Arteriosclerosis, thrombosis, and vascular biology2019

DOI: 10.1161/atvbaha.119.313247 PMID: 31553664

Something wrong or missing on this profile? Suggest a correction

Robert Day

Research

Latest papers

Latest funding

Enhancing the Drug-Like Profile of a Potent Peptide PACE4 Inhibitor by the Formation of a Host-Guest Inclusion Complex with β-Cyclodextrin.

Cleavage of the V-ATPase associated prorenin receptor is mediated by PACE4 and is essential for growth of prostate cancer cells.

Efficacy of PACE4 pharmacotherapy in JHU-LNCaP-SM preclinical model of androgen independent prostate cancer.

PACE4-altCT isoform of proprotein convertase PACE4 as tissue and plasmatic biomarker for prostate cancer.

Design and Structure-Activity Relationship of a Potent Furin Inhibitor Derived from Influenza Hemagglutinin.

Mast Cell Degranulation Increases Mouse Mast Cell Protease 4-Dependent Vasopressor Responses to Big Endothelin-1 But Not Angiotensin I.

Upregulation of PACE4 in prostate cancer is not dependent on E2F transcription factors.

The motif EXEXXXL in the cytosolic tail of the secretory human proprotein convertase PC7 regulates its trafficking and cleavage activity.

Functional analysis of natural PCSK9 mutants in modern and archaic humans.

Ser-Phosphorylation of PCSK9 (Proprotein Convertase Subtilisin-Kexin 9) by Fam20C (Family With Sequence Similarity 20, Member C) Kinase Enhances Its Ability to Degrade the LDLR (Low-Density Lipoprotein Receptor).

Set-up of a mass spectrometry-based stool test for colorectal cancer screening

High affinity inhibitors of PACE4 with therapeutic implications for prostate cancer

Découverte de biomarqueurs en relation avec la PACE4 à l'aide d'une approche multiomique par spectrométrie de masse pour le cancer de la prostate

Novel mechanism of atherosclerotic plaque progression mediated by mouse Mast Cell Protease-4

Validation of the potential of PACE4 as a marker for prostate cancer diagnosis.

Les fonctions distinctes/redondantes des proprotéines convertases (PCs) dans la physiopathologie du cancer.

Développement d'inhibiteurs moléculaires protéiques dirigés contre la protéine PACE4 à l'aide d'un système de livraison lentiviral

DÉVELOPPEMENT DE PEPTIDES INHIBITEURS DE PACE4 ET LEURS EFFETS SUR LA PROGRESSION TUMORALE

Proprotein Processing, Trafficking, and Secretion Gordon Research Conference

Frequent collaborators

William Muller

Adel Schwertani

Roger LECOMTE

Danielle Jacques

Jean-Pierre Perreault

François Corbin

Yves Dory

Armand Soldera

Klaus Klarskov

Nahum Sonenberg

Jean-Paul Praud

Louis Gendron

Luigi Bouchard

Annik Prat

Ghassan Bkaily

Martin Lepage

Robert Day

Research

Latest papers

Latest funding

Enhancing the Drug-Like Profile of a Potent Peptide PACE4 Inhibitor by the Formation of a Host-Guest Inclusion Complex with &#x3b2;-Cyclodextrin.

Cleavage of the V-ATPase associated prorenin receptor is mediated by PACE4 and is essential for growth of prostate cancer cells.

Efficacy of PACE4 pharmacotherapy in JHU-LNCaP-SM preclinical model of androgen independent prostate cancer.

PACE4-altCT isoform of proprotein convertase PACE4 as tissue and plasmatic biomarker for prostate cancer.

Design and Structure-Activity Relationship of a Potent Furin Inhibitor Derived from Influenza Hemagglutinin.

Mast Cell Degranulation Increases Mouse Mast Cell Protease 4-Dependent Vasopressor Responses to Big Endothelin-1 But Not Angiotensin I.

Upregulation of PACE4 in prostate cancer is not dependent on E2F transcription factors.

The motif EXEXXXL in the cytosolic tail of the secretory human proprotein convertase PC7 regulates its trafficking and cleavage activity.

Functional analysis of natural PCSK9 mutants in modern and archaic humans.

Ser-Phosphorylation of PCSK9 (Proprotein Convertase Subtilisin-Kexin 9) by Fam20C (Family With Sequence Similarity 20, Member C) Kinase Enhances Its Ability to Degrade the LDLR (Low-Density Lipoprotein Receptor).

Frequent collaborators

William Muller

Adel Schwertani

Roger LECOMTE

Danielle Jacques

Jean-Pierre Perreault

François Corbin

Yves Dory

Armand Soldera

Klaus Klarskov

Nahum Sonenberg

Jean-Paul Praud

Louis Gendron

Luigi Bouchard

Annik Prat

Ghassan Bkaily

Martin Lepage

Enhancing the Drug-Like Profile of a Potent Peptide PACE4 Inhibitor by the Formation of a Host-Guest Inclusion Complex with β-Cyclodextrin.